TG68 (Figure 1) is a recently developed THRβ selective thyromimetic produced by our group as a pro-drug of IS25 [24], a novel halogen-free THRβ selective agonist based on the scaffold of sobetirome [30], which has been found to share resmetirom’s capacity to strongly reduce liver fat accumulation in a diet-induced mouse model of NAFLD, thus revealing a good safety profile for long-term therapies [25]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatotic liver disease.